$BDX earnings report

BD reported Q4 revenue of $5,274 million, up 5.4%, and FY2026 revenue of $19,457 million, up 4.9%, while issuing FY2027 adjusted diluted EPS guidance of $13.10 to $13.30. AlphAI read Becton Dickinson's Q4 and FY2026 filing as solid. 2 quarters are on record below.

Q4 and FY2026

AlphAI · Earnings readBDX · Q4 and FY2026 · ended September 30, 2026

BD reported Q4 revenue of $5,274 million, up 5.4%, and FY2026 revenue of $19,457 million, up 4.9%, while issuing FY2027 adjusted diluted EPS guidance of $13.10 to $13.30.

✓Solid quarter

Fourth-quarter revenue grew 5.4% as reported across all four continuing-operation segments, adjusted diluted EPS rose 27.3%, and FY2026 free cash flow increased 42.5%. FY2027 guidance calls for low single-digit reported and FXN revenue growth and adjusted diluted EPS of $13.10 to $13.30.

Revenue
$5.27B
5.4 % y/y
Q4 FY2026 Medical Essentials
$1.79B
5.9 % y/y
EPS · non-GAAP
$ 4.15
27.3 % y/y
Full Year FY2027 outlook
Reported Revenue Growth: Low single-digit; Revenue Growth (FXN): Low single-digit

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q4 FY2026 total revenuesGAAP$5.27B–5.4 %
Q4 FY2026 total revenues foreign currency neutral changenon-GAAP5.6 %–5.6 %
Q4 FY2026 cost of products soldGAAP2.58B–(2.2) %
Q4 FY2026 selling and administrative expenseGAAP1.26B–4.4 %
Q4 FY2026 research and development expenseGAAP246M–(6.8) %
Q4 FY2026 integration, restructuring and transaction expenseGAAP77M–(38.7) %
Q4 FY2026 other operating expense, netGAAP76M–(67.0) %
Q4 FY2026 total operating costs and expensesGAAP4.24B–(5.1) %
Q4 FY2026 operating incomeGAAP1.03B–92.5 %
Q4 FY2026 income from continuing operations before income taxesGAAP901M–155.8 %
Q4 FY2026 income tax provisionGAAP209M–3,049.1 %
Q4 FY2026 net income from continuing operationsGAAP692M–100.2 %
Q4 FY2026 net incomeGAAP$696M–41.2 %
Q4 FY2026 diluted earnings per share from continuing operationsGAAP$ 2.52–110.0 %
Q4 FY2026 diluted earnings per shareGAAP$ 2.54–47.7 %
Q4 FY2026 adjusted diluted earnings per share from continuing operationsnon-GAAP$ 4.15–27.3 %
FY2026 total revenuesGAAP$19.46B–4.9 %
FY2026 total revenues foreign currency neutral changenon-GAAP3.9 %–3.9 %
FY2026 cost of products soldGAAP10.24B–(0.4) %
FY2026 total operating costs and expensesGAAP17.20B–3.6 %
FY2026 operating incomeGAAP2.26B–16.3 %
FY2026 net income from continuing operationsGAAP1.42B–28.7 %
FY2026 net incomeGAAP$1.15B–(31.7) %
FY2026 diluted earnings per share from continuing operationsGAAP$ 5.06–32.8 %
FY2026 diluted earnings per shareGAAP$ 4.09–(29.7) %
FY2026 adjusted diluted earnings per share from continuing operationsnon-GAAP$ 12.70–6.7 %
FY2026 net cash provided by continuing operating activitiesGAAP$3.60B–30.0 %
FY2026 capital expendituresGAAP−672M–(6.0) %
FY2026 free cash flownon-GAAP$2.93B–42.5 %
September 30, 2026 cash and equivalentsGAAP$725M––
September 30, 2026 current debt obligationsGAAP$2.92B––
September 30, 2026 long-term debtGAAP$13.42B––

Segments

SegmentRevenueq/qy/y
Q4 FY2026 Medical EssentialsMedication Delivery Solutions revenue was $ 1,256 million, up 4.5 %, and Specimen Management revenue was 529 million, up 9.5 %.$1.79B–5.9 %
Q4 FY2026 Connected CareMedication Management Solutions revenue was $ 952 million, down (2.3) %, while Advanced Patient Monitoring revenue was 317 million, up 15.0 %.$1.27B–1.6 %
Q4 FY2026 BioPharma SystemsReported growth was 6.5 % and foreign currency neutral growth was 7.0 %.$748M–6.5 %
Q4 FY2026 InterventionalPeripheral Intervention revenue was $ 577 million, up 8.8 %; Urology and Critical Care revenue was 473 million, up 8.2 %; and Surgery revenue was 422 million, up 5.5 %.$1.47B–7.6 %
FY2026 Medical EssentialsMedication Delivery Solutions revenue was $ 4,711 million, up 3.0 %, and Specimen Management revenue was 1,992 million, up 6.5 %.$6.70B–4.0 %
FY2026 Connected CareMedication Management Solutions revenue was $ 3,530 million, up 1.6 %, while Advanced Patient Monitoring revenue was 1,215 million, up 12.2 %.$4.75B–4.1 %
FY2026 BioPharma SystemsReported growth was 4.8 % and foreign currency neutral growth was 3.3 %.$2.44B–4.8 %
FY2026 InterventionalPeripheral Intervention revenue was $ 2,129 million, up 6.7 %; Urology and Critical Care revenue was 1,770 million, up 7.4 %; and Surgery revenue was 1,673 million, up 6.4 %.$5.57B–6.8 %

Full Year FY2027 outlook

  • RevenueReported Revenue Growth: Low single-digit; Revenue Growth (FXN): Low single-digit
  • NoteAdjusted Diluted EPS: $13.10 to $13.30
  • NoteReported % Change in adjusted diluted EPS: +3.1% to +4.7%
  • NoteIllustrative Foreign Currency (FX) Impact: ~(70) basis points

Capital returns

  • Repurchases of common stock: (2,433) million in FY2026, compared with (1,000) million in FY2025.
  • Dividends paid: (1,161) million in FY2026, compared with (1,196) million in FY2025.
  • Distribution from spin-off entity, net: 3,916 million in FY2026.

What drove it

  • Q4 revenue increased 5.4 % as reported and 5.6 % FXN, with United States revenue of $ 3,204 million, up 4.3 %, and International revenue of $ 2,070 million, up 7.0 %.
  • All four Q4 continuing-operation segments posted reported revenue growth, led by Interventional at 7.6 % and BioPharma Systems at 6.5 %.
  • Q4 operating income increased 92.5 % to 1,032 million as total operating costs and expenses declined 5.1 % to 4,242 million.
  • FY2026 net cash provided by continuing operating activities increased 30.0 % to $ 3,605 million and free cash flow increased 42.5 % to $ 2,933 million.
  • The company completed the spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters on February 9, 2026. Historical Life Sciences results are presented as discontinued operations and prior periods were recast.

Concerns

  • Q4 Connected Care grew 1.6 %, with Medication Management Solutions revenue declining (2.3) % to $ 952 million.
  • FY2026 GAAP net income declined (31.7) % to $ 1,145 million and GAAP diluted earnings per share declined (29.7) % to $ 4.09, reflecting a (Loss) from discontinued operations, net of tax of (271) million.
  • FY2026 integration, restructuring and transaction expense increased 100.2 % to 806 million. Restructuring costs included non-cash asset impairment charges of $450 million.
  • FY2027 reported and FXN revenue growth guidance is Low single-digit.
  • Management stated that tariffs, international trade policies and related countermeasures are rapidly evolving and that there can be no assurance of the ultimate impact on guidance and results of operations.

What to watch

  • FY2027 reported revenue growth guidance of Low single-digit and illustrative FX impact of ~(70) basis points.
  • FY2027 adjusted diluted EPS guidance of $13.10 to $13.30.
  • Connected Care performance, particularly Medication Management Solutions after its Q4 revenue decline of (2.3) %.
  • Execution of the U.S. Government partnership, under which BD intends to invest $19 billion in the U.S. over several years, including $3 billion toward manufacturing expansion.
  • The company’s 2026 Investor Day on December 10th at the New York Stock Exchange.

Balance sheet and cash flow

  • Cash and equivalents were $ 725 million at September 30, 2026, versus $ 567 million at September 30, 2025.
  • Restricted cash was 284 million at September 30, 2026, versus 210 million at September 30, 2025.
  • Current debt obligations were $ 2,923 million at September 30, 2026, versus $ 1,559 million at September 30, 2025.
  • Long-term debt was 13,422 million at September 30, 2026, versus 17,620 million at September 30, 2025.
  • FY2026 payments of debt were (2,696) million; proceeds from long-term debt were 704 million.
  • FY2026 net cash used for continuing investing activities was (1,010) million, compared with (673) million in FY2025.
  • Closing cash and equivalents and restricted cash were $ 1,010 million, compared with $ 777 million.

Analysis

BD closed FY2026 with Q4 continuing-operations revenue of $5,274 million, up 5.4 % as reported and 5.6 % FXN. Revenue growth was broad across the four operating segments: Medical Essentials grew 5.9 %, Connected Care grew 1.6 %, BioPharma Systems grew 6.5 %, and Interventional grew 7.6 %. Interventional was the largest Q4 growth contributor among the reported segments, while Connected Care was held back by a (2.3) % decline in Medication Management Solutions despite 15.0 % growth in Advanced Patient Monitoring.

Q4 profitability rose sharply on a GAAP basis. Operating income was 1,032 million, up 92.5 %, as cost of products sold declined (2.2) %, integration, restructuring and transaction expense declined (38.7) %, and other operating expense, net declined (67.0) %. Diluted EPS from continuing operations was $ 2.52, up 110.0 %, while adjusted diluted EPS from continuing operations was $ 4.15, up 27.3 %. The reconciliation identifies a $66 million benefit, primarily in cost of products sold, related to refunds of tariffs imposed under IEEPA, alongside net charges of $45 million in other operating expense, net related to product liability and certain other legal matters.

For the full year, revenue increased 4.9 % to $19,457 million, or 3.9 % FXN, and operating income increased 16.3 % to 2,257 million. Net income from continuing operations rose 28.7 % to 1,417 million and FY2026 adjusted diluted EPS rose 6.7 % to $12.70. Reported net income and total diluted EPS declined because discontinued operations produced a (271) million loss, net of tax, after the February 9, 2026 spin-off and combination of the former Biosciences and Diagnostic Solutions business with Waters. The year also included 806 million of integration, restructuring and transaction expense, including $450 million of non-cash asset impairment charges.

Cash generation strengthened materially. Net cash provided by continuing operating activities increased 30.0 % to $3,605 million, and free cash flow increased 42.5 % to $2,933 million. BD used (2,433) million for common-stock repurchases and paid (1,161) million in dividends, while also making (2,696) million of debt payments. At September 30, 2026, long-term debt was 13,422 million, down from 17,620 million, while current debt obligations were 2,923 million, up from 1,559 million.

FY2027 guidance calls for Low single-digit reported revenue growth, Low single-digit FXN revenue growth, and adjusted diluted EPS of $13.10 to $13.30. The company disclosed an illustrative foreign-currency impact of ~(70) basis points and stated that its adjusted EPS outlook excludes potential charges or gains, including non-cash amortization of intangible assets, acquisition-related charges, separation-related costs, and certain tax matters. Management also highlighted a planned $19 billion U.S. investment over several years, including $3 billion toward manufacturing expansion, under a partnership with the U.S. Government.

Management, verbatim

We delivered a strong fourth quarter, with 5.6% revenue growth and broad-based performance led by our key growth platforms.

Tom Polen, chairman, CEO and president of BD

Fiscal 2026 was a defining year as we completed BD's transformation to a more focused MedTech company with separation of our Life Sciences business.

Tom Polen, chairman, CEO and president of BD

We enter fiscal 2027 from a position of strength, with a portfolio built for durable performance and confidence in the long-term growth, earnings and cash-flow potential of New BD.

Tom Polen, chairman, CEO and president of BD

Not in the filing

stated, not guessed
  • Prior-period outlook was not provided, so no comparison of actual results with prior guidance is available.
  • Q4 and FY2026 gross margin were not reported.
  • Quarterly operating cash flow and quarterly free cash flow were not reported.
  • FY2027 gross margin, operating-expense, tax-rate, operating-cash-flow, free-cash-flow, capital-expenditure, dividend, and repurchase guidance were not reported.
  • FY2027 GAAP diluted EPS guidance was not reported; the company did not provide a reconciliation of adjusted diluted EPS guidance to the comparable GAAP measure.
  • Sequential quarter comparisons were not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Q3 FY2026

AlphAI · Earnings readBDX · Third Quarter Fiscal 2026 · ended June 30, 2026

BD Reports Third Quarter Fiscal 2026 Financial Results

✓Strong quarter

Revenue increased 5.4% as reported and 4.4% FXN, while GAAP and adjusted diluted EPS from continuing operations increased 4.5% and 4.9%, respectively. All four reported operating segments grew, year-to-date cash from continuing operations and free cash flow increased, and the company raised the midpoint of adjusted diluted EPS guidance.

Revenue
$4.98B
5.4% y/y
Medical Essentials
$1.68B
4.5% y/y
EPS · non-GAAP
3.8%
3.8% y/y
Full Year Fiscal 2026 outlook
GAAP Revenue Growth: Low single-digit plus; Revenue Growth (FXN): Low single-digit

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
RevenuesGAAP$4.98B–5.4%
Revenues foreign currency neutral changenon-GAAP4.4%–4.4%
Reported Diluted Earnings per ShareGAAP$1.64–4.5%
Reported Diluted Earnings per Share foreign currency neutral changenon-GAAP3.8%–3.8%
Adjusted Diluted Earnings per Sharenon-GAAP$3.23–4.9%
Adjusted Diluted Earnings per Share foreign currency neutral changenon-GAAP3.9%–3.9%
United States revenuesGAAP$3.08B–6.9%
International revenuesGAAP$1.90B–3.2%
International revenues foreign currency neutral changenon-GAAP0.6%–0.6%
Year-to-date cash from continuing operationsGAAP$2.1B–33.3%
Year-to-date free cash flownon-GAAP$1.7B–44.6%

Segments

SegmentRevenueq/qy/y
Medical EssentialsNo segment-specific financial driver was disclosed.$1.68B–4.5%
Connected CareNo segment-specific financial driver was disclosed.$1.22B–4.9%
BioPharma SystemsBD announced a collaboration with EMS to expand access to GLP-1 therapies through a semaglutide launch utilizing BD's Vystra™ Injection Pen platform.$670M–6.6%
InterventionalBD launched the Elyra™ Thulium Fiber Laser System, expanding its kidney stone care portfolio.$1.41B–6.4%

Full Year Fiscal 2026 outlook

  • RevenueGAAP Revenue Growth: Low single-digit plus; Revenue Growth (FXN): Low single-digit
  • NoteAdjusted Diluted EPS: $12.62 to $12.72

What drove it

  • United States revenues increased 6.9%, compared with International revenue growth of 3.2% as reported and 0.6% on a foreign currency-neutral basis.
  • All four reported operating segments recorded revenue growth, led by BioPharma Systems at 6.6% and Interventional at 6.4%.
  • The company cited strong momentum across key growth platforms, continued innovation, and further progress through BD Excellence.
  • BD completed the spin-off of its former Biosciences and Diagnostic Solutions business and the combination of that business with Waters on February 9, 2026. Results of the former business are reflected as discontinued operations and prior periods were recast on a continuing operations basis.

Concerns

  • International revenue increased 0.6% on a foreign currency-neutral basis, below United States revenue growth of 6.9%.
  • Full-year adjusted diluted EPS guidance excludes potential charges or gains including non-cash amortization of intangible assets, acquisition-related charges, separation-related costs, and certain tax matters.
  • The company stated that the impact and timing of potential excluded charges or gains are inherently uncertain and difficult to predict.

What to watch

  • Whether revenue growth reaches the high end of the company's full-year GAAP Revenue Growth range of Low single-digit plus.
  • Execution against full-year Revenue Growth (FXN) guidance of Low single-digit.
  • Delivery within the updated full-year Adjusted Diluted EPS range of $12.62 to $12.72.
  • The pace of International revenue growth on a foreign currency-neutral basis.
  • Continued cash generation from continuing operations and free cash flow following the February 9, 2026 transaction.

Balance sheet and cash flow

  • Year-to-date cash from continuing operations increased 33.3% to $2.1 billion.
  • Year-to-date free cash flow increased 44.6% to $1.7 billion.
  • Free cash flow is defined as net cash provided by continuing operating activities less capital expenditures.

Analysis

BD reported third-quarter continuing-operations revenue of $4,983 million, up 5.4% as reported and 4.4% on a foreign currency-neutral basis. GAAP diluted earnings per share rose 4.5% to $1.64, while adjusted diluted earnings per share increased 4.9% to $3.23. The release states that revenue, adjusted operating margin and adjusted EPS were ahead of management's expectations, although it does not disclose the adjusted operating margin figure.

Growth was broad across the four continuing-operations segments. BioPharma Systems produced the highest reported growth at 6.6%, followed by Interventional at 6.4%, Connected Care at 4.9%, and Medical Essentials at 4.5%. Geographic performance was led by the United States, where revenue rose 6.9%. International revenue increased 3.2% as reported but only 0.6% on a foreign currency-neutral basis, making underlying international growth an important point of attention.

Cash generation strengthened in the first nine months of fiscal 2026. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion, and free cash flow increased 44.6% to $1.7 billion. The filing does not provide capital-return activity, cash balances, debt balances, capital expenditures, or a reconciliation of the reported free-cash-flow amount in the provided text.

The results are presented on a continuing-operations basis after the February 9, 2026 spin-off of BD's former Biosciences and Diagnostic Solutions business and its combination with Waters. Prior-period amounts have been recast, which is essential context for interpreting the reported comparisons. BD characterized the quarter as its first full quarter as New BD and highlighted growth-platform momentum, innovation, BD Excellence, and strategic capital allocation.

For full-year fiscal 2026, BD maintained GAAP Revenue Growth guidance at Low single-digit plus and Revenue Growth (FXN) guidance at Low single-digit. It updated adjusted diluted EPS guidance to $12.62 to $12.72 from $12.52 to $12.72, raising the midpoint while retaining the upper end. The company said the outlook reflects assumptions reviewed as of August 6, 2026, and noted that adjusted diluted EPS excludes several potentially material and uncertain items.

Management, verbatim

We delivered a strong third quarter, with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations.

Tom Polen, chairman, CEO and president of BD

Our first full quarter as New BD demonstrates the early benefits of a more focused MedTech company, with strong momentum across our key growth platforms, continued innovation and further progress through BD Excellence.

Tom Polen, chairman, CEO and president of BD

Not in the filing

stated, not guessed
  • Gross profit and gross margin for the third quarter
  • Operating income, adjusted operating income, and operating margin figures for the third quarter
  • GAAP net income from continuing operations for the third quarter
  • Adjusted net income for the third quarter
  • Prior-quarter revenue, EPS, segment revenue, geographic revenue, and cash-flow comparisons
  • Segment foreign currency-neutral revenue-growth rates
  • Third-quarter operating cash flow and free cash flow amounts
  • Capital expenditures
  • Cash and cash equivalents balance
  • Debt balance
  • Share repurchases, dividends, and other capital-return activity
  • Full-year fiscal 2026 GAAP EPS guidance
  • Full-year fiscal 2026 gross-margin, operating-expense, and tax-rate guidance
  • Actual full-year fiscal 2026 results needed to assess prior full-year guidance versus actual performance
  • Complete financial tables and non-GAAP reconciliations, which were not included in the provided filing text

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about BDX earnings dates

When is Becton Dickinson's next earnings date?
AlphAI has no date for BDX yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.